Advances in Treatment of Metastatic Colorectal Cancer

Colorectal cancer (CRC) remains a major health threat in the United States, ranking as the fourth most common cancer among men and women combined.

The VA diagnoses approximately 4,000 new CRC cases annually. More than half of people with CRC either have metastatic disease at diagnosis or will develop it

Recent research in metastatic colorectal cancer (mCRC) demonstrates that personalized therapy outperforms broad approaches to treatment of this challenging malignancy in federal medicine and elsewhere.

Epidermal growth factor receptor (EGFR) inhibitors such as panitumumab are pivotal in treating metastatic colorectal cancer (mCRC) patients with wild-type KRAS mutations in the first, second and third lines, especially in patients with wild-type RAS genes.